News Headlines Article

Glaxo Ordered to End Drug Trial Enrollment
New York Times

The Food and Drug Administration on Wednesday ordered GlaxoSmithKline to stop enrolling people in a controversial clinical trial comparing diabetes drugs.

The F.D.A. also ordered GlaxoSmithKline, the British pharmaceutical giant, to inform the 1,324 people already testing the drugs that its product Avandia may increase heart risks.

The company said it would comply, but maintained Avandia was a safe option for some people with Type 2 diabetes.